WHAT WE DO
We Are Advancing Precision-Engineered, First-In-Class Therapies to Help Patients Fight Serious Lung Diseases
Our Focus Area
At Oncofibro, we are committed to improving lives through precision therapies — advancing innovative treatments for lung diseases like idiopathic pulmonary fibrosis and lung cancer, while bringing new hope in oncology and antiviral care for companion animals.
Science & Technology
At the heart of our technology is Tat-MYC Fusion Protein (Tatmyctofusp) — a recombinant fusion of the HIV-Tat protein transduction domain (PTD) with MYC, a master transcription factor. This unique design enables direct nuclear delivery of MYC into immune cells, bypassing the need for receptors, viral vectors, or gene editing.
Tatmyctofusp reprograms immune cells through a stepwise cascade of metabolic, transcriptional, and checkpoint restoration.
Platforms
Tatmyctofusp is a modular platform technology designed to enhance immune cell performance across multiple therapeutic settings. At the heart of the platform is MYC, a master regulator of cell growth, metabolism and effector function. Whether releasing the brakes (checkpoint inhibitors), tuning the steering (TCR), or building a supercar (CAR-T), Tat-MYC keeps the engine running, the fuel flowing, and the immune response driving tumors down.
Manufacturing
Oncofibro works with various manufacturing partners, utilizing the latest proprietary single- use closed systems for point-of-care cell processing and treatment. Our “GMP-in-a-box” isolators and integrated cell processing systems enable the delivery of point-of-care therapies in an outpatient setting.
Our proprietary cell processing begins with the isolation of PBMCs from whole blood using density gradient centrifugation. The cells are then incubated at room temperature with our patented fusion protein, Tatmyctofusp, followed by cell washing, filling into closed cryovials, and cryopreservation—all completed within a single day.
We are exploring the use of rapid sterility testing to ensure vein-to-vein processing within a target of less than five days.
Advancing Therapies Through Translational Medicine
Disciplined Approach to Medicine and Drug Development
Platform Approach
- Platform Technologies with potential in many indications of high unmet need starting from pets then to lung diseases.
- Deep Global Network Sourcing Globally
- Robust Biological understanding of molecular biology
- Long patent Life
Translational Medicine
- Expert team focused on preclinical pharmacology, toxicology, pharmokinetics and cell based and crispe engines as well as 3D in vitro models to
- Optimize early-stage development
- Develop and screen disease specific models.
Patient First Approach
- Focused on lowest costs of goods to ensure coverage by medical insurance whilst maintaining profit
- Differentiated first in class targets and platforms
- Outsourcing so that company remains knowledge intensive and capex light to focus on development of new assets.
